H.C. Wainwright maintains Leap Therapeutics at 'buy' with a price target of $7.00

An analyst from H.C. Wainwright maintained Leap Therapeutics (NASDAQ: LPTX ) at 'buy' with a price target of $7.00 from a prior price target of $2.50.
Prior to this rating, Leap Therapeutics had 5 buy ratings, 0 hold ratings, and 0 sell ratings.
For consensus analyst estimates and price targets on Leap Therapeutics, click here. For more news on Leap Therapeutics, click here.
Leap Therapeutics's stock price closed at $2.4000. They are down -21.57% in the last month and down -82.7300% in the last 12 months.
According to Investing Pro, Leap Therapeutics's fair value is $2.5484, an upside of 6.1825%. Leap Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.
Check out Leap Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or